[1] Xia SL, Zhang YT, Wang YX, Wang H, Yang YK, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21(1):39 − 51. http://dx.doi.org/10.1016/S1473-3099(20)30831-8CrossRef
[2] Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, Zhang YD, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy 2021;76(2):551 − 61. http://dx.doi.org/10.1111/all.14622CrossRef
[3] Feng X, Yin JM, Zhang JY, Hu YL, Ouyang YB, Qiao SB, et al. Longitudinal profiling of antibody response in patients with COVID-19 in a tertiary care hospital in Beijing, China. Front Immunol 2021;12:614436. http://dx.doi.org/10.3389/fimmu.2021.614436CrossRef
[4] Florescu L, Rugina A, Temneanu OR, Paduraru DTA, Matei MC, Safta C, et al. Vaccination--collective responsibility or violation of rights? Rev Med Chir Soc Med Nat Iasi 2015;119(4):1098–105. https://pubmed.ncbi.nlm.nih.gov/26793855/
[5] Centers for Disease Control and Prevention. COVID-19 breakthrough case investigations and reporting. 2021. https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html. [2021-4-19].https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html
[6] Ma CF, Xu ST, Yao YC, Yu PB, Xu Y, Wu R, et al. Outbreak reports: mild breakthrough infection in a healthcare professional working in the isolation area of a hospital designated for treating COVID-19 patients—Shaanxi Province, China, March, 2021. China CDC Wkly 2021;3(19):397 − 400. http://dx.doi.org/10.46234/ccdcw2021.094CrossRef
[7] Zhou HR, Wang XL, Xu QF, Wang XM, Ma YD, Shi YR, et al. Outbreak reports: an investigation of a confirmed imported case of COVID-19 infected abroad—Qingpu District, Shanghai Municipality, China, November 15, 2020. China CDC Wkly 2021;3(10):207 − 10. http://dx.doi.org/10.46234/ccdcw2021.061CrossRef